共 50 条
- [1] NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Fehrenbacher, LouisJeong, Jong-HyeonRastogi, PriyaGeyer, Charles E.Paik, SoonmyungGanz, Patricia A.Land, Stephanie R.Costantino, Joseph P.Swain, Sandra M.Mamounas, Eleftherios P.Wolmark, Norman
- [2] NSABP B-47: A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.CANCER RESEARCH, 2011, 71Fehrenbacher, L.Jeong, J-HRastogi, P.Geyer, C. E.Paik, S.Ganz, P. A.Land, S. R.Costantino, J. P.Swain, S. M.Mamounas, E. P.Wolmark, N.
- [3] NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+or 2+with negative FISH (HER2-Low IBC)CANCER RESEARCH, 2018, 78 (04)Fehrenbacher, LouisCecchini, Reena S.Geyer, Charles E.Rastogi, PriyaCostantino, Joseph P.Atkins, James N.Polikoff, JonathanBoileau, Jean-FrancoisProvencher, LoiuseStokoe, ChristopherMoore, Timothy D.Robidoux, AndreBorges, VirginiaAlbain, Kathy S.Swain, Sandra M.Paik, SoonmyungMamounas, Eleftherios P.Wolmark, Norman
- [4] NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05) : 444 - 453Fehrenbacher, LouisCecchini, Reena S.Geyer, Charles E., Jr.Rastogi, PriyaCostantino, Joseph P.Atkins, James N.Crown, John P.Polikoff, JonathanBoileau, Jean-FrancoisProvencher, LouiseStokoe, ChristopherMoore, Timothy D.Robidoux, AndreFlynn, Patrick J.Borges, Virginia F.Albain, Kathy S.Swain, Sandra M.Paik, SoonmyungMamounas, Eleftherios P.Wolmark, Norman
- [5] Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancerCANCER, 2011, 117 (24) : 5461 - 5468McArthur, Heather L.Mahoney, Kathleen M.Morris, Patrick G.Patil, SujataJacks, Lindsay M.Howard, JaneNorton, LarryHudis, Clifford A.
- [6] Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast CancerJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (01): : 47 - 56Veitch, ZacharyKhan, Omar F.Tilley, DerekRibnikar, DomekKostaras, XanthoulaKing, KarenTang, PatriciaLupichuk, Sasha
- [7] Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 TrialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3197 - +Swain, Sandra M.Tang, GongGeyer, Charles E., Jr.Rastogi, PriyaAtkins, James N.Donnellan, Paul P.Fehrenbacher, LouisAzar, Catherine A.Robidoux, AndrePolikoff, Jonathan A.Brufsky, Adam M.Biggs, David D.Levine, Edward A.Zapas, John L.Provencher, LouiseNorthfelt, Donald W.Paik, SoonmyungCostantino, Joseph P.Mamounas, Eleftherios P.Wolmark, Norman
- [8] Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancerCANCER RESEARCH, 2013, 73Slamon, D. J.Swain, S. M.Buyse, M.Martin, M.Geyer, C. E.Im, Y-HPienkowski, T.Kim, S-BRobert, N. J.Steger, G.Crown, J.Verma, S.Eiermann, W.Costantino, J. P.Im, S-AMamounas, E. P.Schwartzberg, L.Paterson, A.Mackey, J. R.Provencher, L.Press, M. F.Thirlwell, M.Bee-Munteanu, V.Henschel, V.Crepelle-Flechais, A.Wolmark, N.
- [9] Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)McArthur, H. L.Mahoney, K.Morris, P. G.Patil, S.Jacks, L. M.Howard, J.Norton, L.Hudis, C.
- [10] Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) : 2621 - +Miller, Kathy D.O'Neill, AnneGradishar, WilliamHobday, Timothy J.Goldstein, Lori J.Mayer, Ingrid A.Bloom, StuartBrufsky, Adam M.Tevaarwerk, Amye J.Sparano, Joseph A.Le-Lindqwister, Nguyet AnhHendricks, Carolyn B.Northfelt, Donald W.Dang, Chau T.Sledge, George W., Jr.